Good news
Recently, Salubris announced that the new anti-hypertension drug “Allisartan and Amlodipine tablets” (FoLitan®) had obtained the drug registration certificate issued by NMPA.
Allisartan and Amlodipine tablets (FoLitan®), a domestic original ARB/CCB compound preparation(Project code: SAL0107), is used for the treatment of essential hypertension, indicated for adult patients with poor blood pressure control treated with Allisartan Isoproxil alone or Amlodipine alone.
Allisartan and Amlodipine tablets (FoLitan®) have classic components, high reliability, and well-proven antihypertensive efficacy. After the launch of the product, it will be targeting hypertension patients in varied segments, and form strategic synergy with Salubris’ listed class 1 innovative drug Xinlitan (Allisartan Isoproxil tablets) in multiple channels, enriching the innovative product pipeline in the field of hypertension, and enhance Salubris’ comprehensive competitiveness in the field of chronic disease.
| General information of drug registration certificate
· Generic name: Allisartan and Amlodipine tablets
· Dosage forms: tablet
· Strengths: Allisartan Isoproxil 240mg and Amlodipine besylate (as measured by amlodipine) 5mg tablets
· Registration classification: Chemical 2.3
· Drug approval number: 国药准字H20240016
